Open Access

Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer

  • Authors:
    • Xianjing Zhang
    • Mingzhu Lu
    • Jing Zhu
    • Changsong Zhang
    • Meihua Wang
  • View Affiliations

  • Published online on: November 24, 2022     https://doi.org/10.3892/etm.2022.11728
  • Article Number: 29
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Esophageal cancer has high incidence rate in China. Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for esophageal squamous cell carcinoma (ESCC). However, there are few reliable epigenetic parameters for patients with ESCC undergoing neoadjuvant therapy. Genomic extract from tumor tissue was amplified and sequenced using the Illumina HiSeq4000 to quantify genes associated methylation or hydromethylation in 12 patients with ESCC undergoing nCRT. The genome‑wide hydroxymethylation were analyzed by methylated and hydroxymethylated DNA immunoprecipitation sequencing by MACS2 software and UCSC RefSeq database. Abnormal DNA methylation was statistically different between nCRT‑well (showed a pathological complete response to nCRT) and nCRT‑poor (showed incomplete pathological response to nCRT) patients. Levels of ten‑eleven translocation 1, 2 and 3 mRNA and protein were higher in tumor tissue in nCRT‑well group patients than in nCRT‑poor group patients. Illumina HiSeq 4000 sequencing identified 2925 hypo‑differentially hydroxymethylated region (DhMRs) and 292 hyper‑DhMRs in promoter between nCRT‑well and nCRT‑poor patients. Biological processes associated with hyper‑DhMRs included ‘snRNA processing’, ‘hormone‑mediated signaling pathway’ and ‘cellular response’. Metabolic processes were associated with hypo‑DhMRs. These data may explain the functional response to nCRT in patients with abnormal promoter of methylation gene‑associated mRNA expression. The present results implied that hyper‑DhMRs and hypo‑DhMRs affect molecular pathways, such as hippo and Notch signaling pathways, highlighting epigenetic modifications associated with clinical response to nCRT in patients with esophageal cancer.

Related Articles

Journal Cover

January-2023
Volume 25 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Lu M, Zhu J, Zhang C and Wang M: Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer. Exp Ther Med 25: 29, 2023
APA
Zhang, X., Lu, M., Zhu, J., Zhang, C., & Wang, M. (2023). Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer. Experimental and Therapeutic Medicine, 25, 29. https://doi.org/10.3892/etm.2022.11728
MLA
Zhang, X., Lu, M., Zhu, J., Zhang, C., Wang, M."Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer". Experimental and Therapeutic Medicine 25.1 (2023): 29.
Chicago
Zhang, X., Lu, M., Zhu, J., Zhang, C., Wang, M."Altered genome‑wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer". Experimental and Therapeutic Medicine 25, no. 1 (2023): 29. https://doi.org/10.3892/etm.2022.11728